Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) disclosed that its investigational small‑molecule, Telomir‑1, killed aggressive human leukemia (HL60) cells in a laboratory study, adding a new blood‑cancer indication to the drug’s preclinical portfolio.
The HL60 experiment showed a dose‑dependent reduction in viable leukemia cells, driven by Telomir‑1’s ability to modulate essential metal ions and reverse epigenetic gene silencing. The result extends the compound’s activity beyond the triple‑negative breast, pancreatic, and aggressive prostate cancer models previously reported, underscoring the platform’s potential to target diverse tumor types.
Telomir remains a preclinical‑stage company with no revenue and a negative earnings‑per‑share of –$0.37. Its balance sheet is strong, with a current ratio of 17.5, a quick ratio of 17.5, and no long‑term debt, giving it ample liquidity to pursue clinical development of Telomir‑1.
Chief Scientific Advisor Dr. Itzchak Angel noted that the potency observed in HL60 cells is consistent with the broader biological patterns seen across Telomir’s research, reinforcing the company’s scientific framework for evaluating the lead candidate and informing the ongoing oncology program.
The announcement triggered a 7.9% pre‑market jump in TELO shares, reflecting investor enthusiasm for the expanded indication and the validation of the metal‑ion regulator platform. The data strengthen Telomir’s case for advancing Telomir‑1 into clinical trials and may broaden the company’s future therapeutic pipeline.
Future milestones will include the initiation of a Phase I study of Telomir‑1 in patients with relapsed or refractory leukemia, contingent on regulatory approval and funding. The company’s strong liquidity positions it to support this next development phase while continuing to explore additional indications within its platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.